Results of treatment of gestational trophoblastic neoplasia in the Slovak Republic in the years 1993–2017
Authors:
Korbeľ M. 1,2; Iarsky Šufl J. 1,3; Danihel Ľ. 1,4; Nižňanská Z. 1,2
Authors‘ workplace:
Centrum pre gestačnú trofoblastovú chorobu Slovenskej republiky, Bratislava, Slovenská republika
1; I. gynekologicko-pôrodnícka klinika LF UK a UN Bratislava, Slovenská republika
2; Oddelenie klinickej onkológie A, II. onkologická klinika LF UK a NOÚ Bratislava, Slovenská republika
3; Ústav patologickej anatómie, LF UK a UN Bratislava, Slovenská republika
4
Published in:
Ceska Gynekol 2021; 86(2): 94-101
Category:
Original Article
doi:
https://doi.org/10.48095/cccg202194
Overview
Objective: Gestational trophoblastic neoplasia epidemiology and treatment results in the Slovak Republic in the years 1993–2017. Methods: Retrospective analysis results of gestational trophoblastic neoplasia treatment in the Centre for gestational trophoblastic disease in the Slovak Republic in Bratislava in the years 1993–2017 according to prognostic scoring and staging system FIGO/WHO (International Federation of Gynecology and Obstetrics/World Health Organization). Results: The Centre for Gestational Trophoblastic Disease was created in the Slovak Republic in the year 1993, after the split of former Czechoslovakia. A total of 100 patients with gestational trophoblastic neoplasia were treated in this Centre in the years 1993–2017. According to prognostic scoring and staging system FIGO/ WHO, 74% patients were at a low risk and 26% of patients were at a high-risk of gestational trophoblastic neoplasia. There were 56, 2, 32 and 10% patients in stages I, II, III, and IV, respectively. The total curability and mortality rates were 96 and 4%, respectively. The curability rate 100% was achieved in stages I–III and in all placental site trophoblastic tumours, and the curability rate 60% was achieved in stage IV. In the years 1993 –2017, the incidences were 1 in 59,315 pregnancies and 1 in 42,299 deliveries for choriocarcinoma, 1 in 489,348 pregnancies and 1 in 348,965 deliveries for placental site trophoblastic tumours, 1 in 139,814 pregnancies and 1 in 99,704 deliveries for invasive mole, and 1 in 39,947 pregnancies and 1 in 28,487 deliveries for persistent gestational trophoblastic neoplasia. In the Czech Republic in the same period of time, there were treated 281 (301) patients with the curability rate 98.6% (98.7%). Conclusion: The results of the treatment of gestational trophoblastic neoplasia in the Slovak Republic are comparable with those achieved by leading centers specialized for the treatment of this disease in Europe and in the world. Early detection and centralisation of the treatment are crucial points for successful treatment, as the high curability rate of gestational trophoblastic neoplasia is achieved by effective therapy.
Keywords:
gestational trophoblastic neoplasia – choriocarcinoma – placental site trophoblastic tumour – epithelioid trophoblastic tumour – invasive mole – curability – mortality – reproductive outcomes
Sources
1. Braga A, Mora P, de Melo AC et al. Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide. World J Clin Oncol 2019; 10(2): 28–37. doi: 10.5306/ wjco.v10.i2.28.
2. Brown J, Naumann RW, Seckl MJ et al. 15 years of progress in gestational trophoblastic disease: scoring, standardization, and salvage. Gynecol Oncol 2016; 144(1): 200–207. doi: 10.1016/ j.ygyno.2016.08.330.
3. Hron F, Feyereisl J, Zavadil M. Výsledky léčby gestačních trofoblastických tumorů v ČR. Gynekol Prax 2014; 12(3): 127–131.
4. Korbeľ M, Šufliarsky J, Danihel Ľ et al. Liečba gestačných trofoblastových tumorov v Slovenskej republike v rokoch 1993–2012. Gynekol Prax 2014; 12(3): 132–135.
5. Li MC, Hertz R, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Biol Med 1956; 93(2): 361–369. doi: 10.3181/ 00379727-93-22757.
6. Ngan HY, Seckl MJ, Berkowitz RS et al. Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet 2018; 143(Suppl 2): 79–85. doi: 10.1002/ ijgo.12615.
7. Seckl MJ, Sebire NJ, Fischer RA et al. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi39–vi50. doi: 10.1093/ annonc/ mdt345.
8. Gazárek F, Kudela M, Lindner E. Naše zkušenosti s léčbou choriokarcinomu. Ceska Gynekol 1976; 41: 273–275.
9. Kudela M, Gazárek F, Fingerova H. Diagnostik und terapie bösartiger trofoblasttumoren. Acta Univ Palacky Olom 1979; 90: 213–216.
10. Skřivan J, Zavadil M, Jakoubková J et al. Péče o ženy s trofoblastickou nemocí (choriokarcinomem) v ČSSR. Prakt Lék 1982; 62(18): 546–547.
11. Zavadil M, Skřivan J, Rob L et al. Centrum pro trofoblastickou nemoc (CTN). Ceska Gynekol 1988; 53(9): 695–700.
12. Zavadil M, Feyereisl J, Krofta L et al. Perzistující trofoblastická nemoc v Centru pro trofoblastickopu nemoc v ČR v létech 1955–2007. Ceska Gynekol 2008; 73(2): 73–79.
13. Korbeľ M, Šufliarsky J, Danihel Ľ et al. Výsledky liečby gestačnej trofoblastovej neoplázie v Slovenskej republike v rokoch 1993–2012. Ceska Gynekol 2016; 81(1): 6–13.
14. Rob L, Zavadil M, Vlachová J. Těhotenství po chemoterapii u maligních forem gestační trofoblastické nemoci. Sborník Lékařský 1993; 94(2): 185–189.
15. Korbeľ M, Danihel Ľ, Vojtaššák J et al. Centrum pre trofoblastovú chorobu Slovenskej republiky – 10 rokov činnosti. Slov Gynek Pôrod 2003; 10(2): 56–61.
16. FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. Int J Gynecol Obstet 2000; 77(3): 285–287. doi: 10.1016/ s0020-7292(02)00063-2.
17. Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med 2002; 47(6): 445–500.
18. WHO. Gestational trophoblastic diseases: report of a WHO scientific group. World Health Organ Tech Rep Ser 1983; 692: 7–81.
19. Danihel Ľ, Čierna Z, Šišovský V et al. Histopatologická diagnostika gestačných trofoblastových tumorov. Gynekol Prax 2014; 12(3): 150–153.
20. Genest DR, Berkowitz RS, Fisher RA et al. Gestational trophoblastic disease. In: Tavassoli FA, Devilee P, WHO classification of tumours (eds). Pathology and genetics, tumours of the breast and female genital organs. Tumours of the uterine corpus. 3rd ed. Lyon: IARC Press 2003: 250–254.
21. Utracká E. Fertilita po chemoterapii pro gestační trofoblastickou nemoc. Gyn Por 2020; 4(1): 30–32.
22. Lin LH, Maestá I, Braga A et al. Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: a retrospective multicenter cohort and literature review. Gynecol Oncol 2017; 145(1): 88–95. doi: 10.1016/ j.ygyno.2017.01.021.
23. SVOD. Epidemiologie zhoubných nádorů v České republice. 2021 [online]. Dostupné na: www.svod.cz.
24. Alifrangis C, Agarwal R, Short D et al. EMA/ CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetics analysis. J Clin Oncol 2013; 31(2): 280–286. doi: 10.1200/ JCO.2012.43.1817.
25. Bolze PA, Patrier S, Massardier J et al. PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes. Int J Gynecol Cancer 2017; 27(3): 554–561. doi: 10.1097/ IGC.0000000000000892.
26. Bolze PA, Attia J, Massardier J et al. Formalised consensus of the European Organisation for Treatment of Trophoblastic Diseases on management of gestational trophoblastic diseases. Eur J Cancer 2015; 51(13): 1725–1731. doi: 10.1016/ j.ejca.2015.05.026.
27. Clair KH, Gallegos N, Bristow RE. Succesful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: a case for immune checkpoint salvage therapy in trophoblastic tumors. Gynecol Oncol Rep 2020; 34: 100625. doi: 10.1016/ j.gore.2020.100625.
28. Sharami SR, Saffarieh E. A review on management of gestational trophoblastic neoplasia. J Family Med Prim Care 2020; 9(3): 1287–1295. doi: 10.4103/ jfmpc.jfmpc_876_19.
29. You B, Bolze PA, Lotz JP et al. Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN phase II trial. J Clin Oncol 2020; 38(27): 3129–3137. doi: 10.1200/ JCO.20.00803.
30. Vargas R, Barroilhet LM, Esselen K et al. Subsequent pregnancy outcome after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 2014; 59(5–6): 188–194.
31. Garcia MT, Lin LH, Fushida K et al. Pregnancy outcomes after chemotherapy for frophoblastic neoplasia. Rev Assoc Med Bras 2016; 62(9): 837–842. doi: 10.1590/ 1806-9282.62.09.837.
32. Mogensen B. Invasive mole and gestational choriocarcinoma in Denmark, 1940–1969: biological and clinical aspects. Acta Obstet Gynec Scand 1973; 52(3): 211–220. doi: 10.3109/ 00016347309158317.
Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineArticle was published in
Czech Gynaecology
2021 Issue 2
Most read in this issue
- Current possibilities in the prevention and therapy of ovarian hyperstimulation syndrome
- Giant breast fibroadenoma in pregnancy
- Obstetric anal sphincter injury and anal incontinence
- A new instrument to personalize ovarian stimulation: results of the CERES study after using a novel gonadotropin – follitropin delta